抄録
This report is to outline the clinical effects of 2-ethyl-3 (4' hydroxybenzole) benzofurane (Fragivix), flavone derivative, on subiects with fragile capillaries as for capillary resistance as well as permeability.
Materials and Methods: Out of hypertensives and diabetics, 23 cases with capillary resistance below 130 mmHg according to Borbély's method were selected. Landis' method was employed for the permeability. The subjects received 600 mg Fragivix a day for a week or two.
Results: Those who showed increase in the capillary resistance more than 30 mmHg by Borbély's method were considered to be effective. Eighteen (78%) among 23 cases were found to be improved in the capillary resistance; bleeding clotting time were unchanged. The inhibition of permeability caused the decrease of water to 90% and protein to 80%, when compared with the results before the administration. Further, side effects were not seen.
The acceleration of peripheral vascular permeability and the decrease of capillary resistance at the same time have been recognized in various constitutional diseases. The author thinks it necessary to normalize the capillary resistance in terms of the prevention of hypertensive cerebral hemorrhage or vascular reinforcement and that of diabetic vascular disease and its improvement. Therefore, Fragivix seems to be of value when used to hypertensive or diabetic patients with fragile capillaries.
